StockNews.com Begins Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXSFree Report) in a report released on Wednesday morning. The brokerage issued a sell rating on the stock.

Ayala Pharmaceuticals Price Performance

NASDAQ ADXS opened at $0.26 on Wednesday. The stock’s 50-day moving average price is $0.38 and its 200-day moving average price is $0.59. Ayala Pharmaceuticals has a 52 week low of $0.14 and a 52 week high of $1.95. The company has a market capitalization of $2.82 million, a P/E ratio of -0.03 and a beta of 1.45.

Ayala Pharmaceuticals (NASDAQ:ADXSGet Free Report) last posted its quarterly earnings data on Tuesday, April 16th. The company reported ($2.96) EPS for the quarter.

About Ayala Pharmaceuticals

(Get Free Report)

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.

Further Reading

Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.